by Paul Fassa
March
12, 2019
from
HealthImpactNews Website
Dr. Kristin Comella
There have been nearly 12,000 adult
stem cell therapies performed in
the United States with an over 90 percent success healing rate for
mostly joint and spinal conditions.
It involves using the patient's
own stem cells, so no patent-able drugs are involved.
They are targeting the most influential stem cell scientist in the
U.S., Dr. Kristin Comella in Florida.
Differentiating the
Types of Stem Cell Therapy
Many consider stem cell therapy 'the future of medicine'...
A stem cell can rebuild or create
new cells in tissues, even in organ tissues other than those from
which they had originally existed.
They could be considered seeds for growing body tissues. They are
mostly able to function for cellular repair and growth no matter
what organ is in need of repair or healing from chronic
inflammation.
There is a considerable controversy surrounding stem cell therapy
research, a branch of regenerative medicine. Much of the
controversy has to do with not differentiating between adult stem
cell therapy and embryonic stem cell therapy.
Embryonic stem cell therapy is the controversial one. It cultures or
creates stem cells from terminated or aborted fetuses.
Currently, the FDA is harassing stem cell clinics that do not derive
their stem cell solutions from aborted fetus tissue. They extract
the stem cells from the patient's own adipose tissue and inject them
into areas where that same patient needs repair.
It's an autologous
process called
adult stem cell therapy.
U.S. Stem Cell based out of South Florida is one of the clinics
being targeted by the FDA, and the clinic's Chief Scientist is Dr.
Kristin Comella, PhD.
Many other nations have been using adult stem cell therapy
successfully over the past 15 years, leaving the USA dead last in
this field. The FDA is trying to make sure it stays that way and
allows costly pharmaceutical versions to prevail.
Dr. Kristin Comella and her clinic have been under attack from
the FDA.
This short 3-minute video was produced interviewing Dr. Comella and
some of her patients:
Examining and
Comparing the Different Types of Stem Cell Therapy
Human embryonic stem cell (hESC) therapy has received most of the
media's attention and government support.
But it is the most
controversial because it involves extracting tissues from terminated
human embryos, aka aborted fetuses.
In addition to moral and ethical issues, human embryonic stem cell (hESC)
solutions create cells so rapidly where they're injected they lead
to cancerous tumors.
To avoid that, researchers have to use immuno-suppressant
drugs to curb the embryonic stem cells' tendency toward cancer.
Using pharmaceutical drugs to curb hESC cancer side effect issues,
leads to other unexplored and unexpected side effects from those
patented stem cell solutions.
But the profit motive for embryonic stem cell therapies was strong
and a lot of government funds had been put into its research.
Pharmaceutical companies were motivated because they could patent
stem cells created from embryonic tissues.
Bone marrow stem cell therapy was among the first to depart from
flawed hESC (human embryonic stem cell) therapies developed over the
past two decades. Bone marrow stem cell therapy was the segue into
the adult stem cell therapy movement.
Bone marrow extractions are painful, requiring general anesthesia.
It's relatively difficult and expensive compared to adipose (fat)
tissue stem cell harvesting.
Bone marrow's high white blood cell count also encourages
inflammation, making it counter-productive for patients already
suffering from chronic inflammation or autoimmune disorders.
Most importantly, adipose (fat) tissue yields up to 500 times more
mesenchymal stem cells than bone marrow sources, according to Dr. Comella.
These are potent stem cells that can differentiate into a
wide variety of other cell types. Furthermore, the adipose white
blood cell count is lower than bone marrow matter.
Overactive, confused immune responses attack organs continually and
create chronic inflammation and
autoimmune diseases.
The lower white
blood cell count automatically lowers the risk of further
inflammation among patients already suffering from chronic
inflammation and autoimmune diseases.
The outpatient treatment involves creating a very small and shallow
incision that won't require stitches on an area of skin covering
adipose tissue (fat).
From there, liposuction can withdraw a portion
of the fat. This part of the procedure requires only a local
anesthetic.
Then what is extracted is spun at high speed in a special centrifuge
to isolate the stem cells which are then purified for IV drip
delivery or injection into the same patient from whom it was
extracted.
Total costs range from five to ten thousand dollars or
more in some cases.
Dr. Comella and her colleagues' mission is to get adult stem cell
therapy available for everyone. Private and government health
insurance providers cover medical treatments that are much more
expensive.
Why not cover one that would save money with its lower expense and
fewer side effects?
Over the years, there have been nearly 12,000 adult stem cell
therapies performed in the United States with an over 90 percent
success healing rate for mostly joint and spinal conditions as well
as heart and lung issues.
But the three known adverse side effect cases continually get all
the media attention.
The Panama College of Cell Science, which helped launch Kristin Comella's research and development, had this to say about her:
Perhaps the most influential clinician on the subject of adult stem
cell therapy, Dr. Comella has been able to quietly develop patient
treatment protocols and treat patients via collaborating physicians
and health care providers using legal patient-specific FDA
guidelines, including studies permitted by Institutional Review
Boards, patient-specific stem cell clinical trials, and direct
treatments using the patients own stem cells that are harvested and
re-injected for therapeutic purposes.
Through Dr. Comella's leadership, she and her team have trained and
certified more than 700 physicians worldwide in adult stem cell
therapy.
Source
The interview below allows the energetic Dr. Kristin Comella to give
a thorough and upbeat description of adult stem cell therapy:
Big Pharma is Using the FDA to Eliminate
"Unregulated" Adult Stem
Cell Competition
Since the late 1990s, adult stem cells used therapeutically were not
under the control of the FDA and the adult stem cell movement took
off.
There were complaints from some MDs that the adult stem cell
practice should be regulated by the FDA.
The Panama College of Cell
Science responded to those outcries with this statement:
The motive in opposing adult stem cell therapy is
money.
The big
institutions want to keep federal funding of embryonic stem cell
research at a high level with the promise that cures are "just
around the corner" despite the fact that embryonic stem cells will
never be useful in any way for patient treatment because they
immediately cause tumors when transplanted.
Source
Adult stem cell therapy is an
autologous treatment method.
The stem
cells are not lab-created. They are only isolated and purified after
extracting them from the patient being treated. Injecting them back
into that patient powers up the body's own healing mechanism to
overcome chronic ailments.
The FDA didn't and shouldn't have anything to do with regulating
stem cells from one's own body. That situation has recently been
arbitrarily and suddenly changed.
Around 2014, the FDA started tweaking their guidance rules for stem
cell therapy with the purpose of getting new rules made into laws
through Congress that could be interpreted according to FDA whims
and enforced arbitrarily.
Their agenda is to consider adult stem
cells as FDA-regulated drugs.
During our phone conversation, Dr. Comella explained how the FDA
ignored testimonies from adult stem cell practitioners during their
2015 public hearings regarding new guideline proposals.
Then they
arranged to create new rules behind closed door meetings that
included
pharmaceutical industry allies and insiders.
The result was that by 2017, the FDA's hands-off policy with adult
stem cell therapy came to a sudden halt after years of highly
successful stem cell practice.
By 2018, the FDA got nastier with the,
"the most influential
clinician on the subject of adult stem cell therapy" as its target.
The FDA started doing inspections of Dr. Comella's South Florida
clinic that are designed for labs that manufacture drugs.
The standards for hospitals and clinics are not as strict as drug
manufacturers. Those inspections were inappropriate for a clinic.
But those inspections made it easier to create damaging reports.
When the inspectors came by, they demanded to go into rooms while
treatments were taking place with semi-nude or nude patients, which
Dr. Comella prohibited.
The inspectors also demanded to view patient
medical records. She allowed that after redacting their names on the
copies she gave them.
For her actions to protect patients' privacy, inspectors allegedly
cited Dr. Comella for resisting and obstructing FDA inspections.
Soon after the inspections, the FDA served Dr. Comella with a
lawsuit for practicing medicine with unapproved drugs. The "drugs"
were only those stem cell solutions drawn from patients to be used
on them.
The FDA has allegedly offered to drop the lawsuit if Dr. Comella
signed an agreement to stop doing adult stem cell therapy and no
longer promote it.
She refused. She said she has witnessed people leave their
wheelchairs for good from this therapy. The trial is set for a
Federal Court hearing beginning June 2019, in Miami, Florida.
If Dr. Comella loses this court case, adult stem cell therapy in the
USA may be forced out of the country and only be available to those
who can afford medical tourism...
|